A detailed history of Vanguard Group Inc transactions in Scynexis Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,686,967 shares of SCYX stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,686,967
Previous 1,687,670 0.04%
Holding current value
$1.7 Million
Previous $3.38 Million 25.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.27 - $2.23 $892 - $1,567
-703 Reduced 0.04%
1,686,967 $2.51 Million
Q1 2024

May 10, 2024

BUY
$1.39 - $2.21 $179,522 - $285,428
129,153 Added 8.29%
1,687,670 $2.48 Million
Q4 2023

Feb 14, 2024

BUY
$1.56 - $2.24 $109,332 - $156,990
70,085 Added 4.71%
1,558,517 $3.48 Million
Q3 2023

Nov 14, 2023

BUY
$1.93 - $3.64 $41,699 - $78,645
21,606 Added 1.47%
1,488,432 $3.39 Million
Q2 2023

Aug 14, 2023

BUY
$2.38 - $3.67 $169,548 - $261,447
71,239 Added 5.1%
1,466,826 $4.33 Million
Q1 2023

May 15, 2023

BUY
$1.15 - $3.0 $83,933 - $218,958
72,986 Added 5.52%
1,395,587 $4.19 Million
Q4 2022

Feb 10, 2023

BUY
$1.46 - $2.94 $916 - $1,846
628 Added 0.05%
1,322,601 $2.06 Million
Q3 2022

Nov 14, 2022

BUY
$1.83 - $2.93 $523,076 - $837,493
285,834 Added 27.59%
1,321,973 $3.17 Million
Q2 2022

Aug 12, 2022

BUY
$1.77 - $3.87 $98,560 - $215,497
55,684 Added 5.68%
1,036,139 $1.93 Million
Q1 2022

May 13, 2022

SELL
$3.56 - $6.66 $11,406 - $21,338
-3,204 Reduced 0.33%
980,455 $3.83 Million
Q4 2021

Feb 14, 2022

BUY
$4.94 - $7.69 $541,690 - $843,239
109,654 Added 12.55%
983,659 $6 Million
Q3 2021

Nov 12, 2021

BUY
$5.3 - $7.89 $6,169 - $9,183
1,164 Added 0.13%
874,005 $4.63 Million
Q2 2021

Aug 13, 2021

BUY
$6.5 - $9.97 $5.67 Million - $8.7 Million
872,841 New
872,841 $6.42 Million

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.